Related references
Note: Only part of the references are listed.Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy
Ming-Yii Huang et al.
WORLD JOURNAL OF SURGERY (2017)
Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy
Y. Y. Zhang et al.
GENETICS AND MOLECULAR RESEARCH (2015)
A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker
Masahiro Hirakawa et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Predictive Value of ERCC1, ERCC2, and XRCC1 Overexpression for Stage III Colorectal Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
Ming-Yii Huang et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients
Yung-Sung Yeh et al.
CHEMOTHERAPY (2012)
Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy
Ming-Yii Huang et al.
PHARMACOGENETICS AND GENOMICS (2011)
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
Stephen B. Edge et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy
K. R. Fareed et al.
BRITISH JOURNAL OF CANCER (2010)
Neoadjuvant Therapy of Locally Advanced Gastric Cancer
James J. Mezhir et al.
JOURNAL OF SURGICAL ONCOLOGY (2010)
Neoadjuvant chemotherapy for advanced gastric cancer: A meta-analysis
Wei Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie
Salah-Eddin Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2007)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer
GR Simon et al.
CHEST (2005)
Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms
J Shia et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer
O Popanda et al.
CARCINOGENESIS (2004)
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
Y Shirota et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
